NattoPharma ASA and PL Thomas Inc., have announced a new strategic alliance to promote the patented MenaQ7 Crystals Natural Vitamin K2 in the dietary supplement, food/beverage and nutricosmetic industries.
PL Thomas and NattoPharma initially joined forces in 2006 to introduce natural vitamin K2 to the nutrition industry under the MenaQ7 brand name. The two companies working jointly have been recognized for pioneering the advent of natural vitamin K2 in dietary supplements to fortify both bone and cardiovascular health. Previous to the initial market launch, vitamin K2 was not recognized for its benefits in these health areas, and through the collaboration, MenaQ7 is now included in leading bone-building formulations in the natural products industry.
"PL Thomas has always been a company that focuses on launching innovative ingredients and being at the forefront of important trends in the nutrition industry," says Paul Flowerman, President. "Our previous work with MenaQ7 has been stimulating because we believe in its place as a necessary nutrient for promoting health in key aging areas, including bone and cardiovascular health. Through NattoPharma's recent work, we are now able to provide a clinically-proven ingredient, recognized with a U.S. patent for cardiovascular applications, to the natural products industry." Dr. Hogne Vik, CEO of NattoPharma, adds, "In the past year, not only have we received intellectual property recognition in Europe and in the US, but also, our groundbreaking three-year clinical study with MenaQ7 for bone health has been published in the prestigious journal Osteoporosis International. In tandem, our study showed significant benefits for arterial health. The patents and the published studies position MenaQ7 for phenomenal growth and sales as its benefits become more widely recognized and consumer demand increases sharply."
The companies are re-launching their strategic partnership after a hiatus of approximately four years. In the past year, NattoPharma underwent significant restructuring, developed the next-generation MenaQ7, received several patents in the EU and US, and has released impressive study results demonstrating that MenaQ7 preserves bone content and strength, as well as demonstrating significant benefits for the promotion of a healthy cardiovascular system.
“This reunion of the two companies that pioneered natural vitamin K2 in North America is a demonstration of each company’s commitment to promoting validated nutritional technologies, and provides opportunities to build significant shareholder value” says Executive Chairman of the Board in NattoPharma, Frode Marc Bohan.